Supplemental Experimental Procedures
coated slides containing PBS/2% CB serum before fixation. All cells were fixed with 4% paraformaldehyde at RT for 10 minutes, permeabilized with PSB/0.1% TX for 10 minutes, blocked with 10% serum (donkey or goat) for 30 minutes at RT, incubated with primary antibodies at 4°C overnight (ON) and then with appropriate secondary antibodies for 1 hour at RT. Slides were mounted with Fluorescence Mounting Medium (Dako, Cambridgeshire, UK) containing DAPI for nuclear staining. Sections were then visualized using a fluorescent microscope (Zeiss AxioVision2; Zeiss, Welwyn Garden City, United Kingdom). Images were acquired using Axiocam MRC with Axiovision 4.7 software. Data was quantified by Imaris ® software (Bitplane, Zurich, Switzerland) and Manders' overlap coefficient was used.
Immunohistochemistry
Paraffin sections (4 m thick) were first de-paraffinized by immersing in Histoclear (RA Lamb, East Sussex, UK), followed by sequential hydrating steps in four decreasing grades of ethanol. Tissue sections were immersed in water before submitting to different antigen retrieval methods. Antigen retrieval was achieved either by microwaving in Citrate buffer (pH 6) or Proteinase K treatment (20 g/ml in Tris-EDTA buffer, pH8) both for 10 minutes (see Table S1 ). Tissue sections were then washed twice with dH 2 O and quenched for endogenous peroxidase for 10 minutes (with 2% H 2 O 2 in PBS). Non-specific staining was blocked with PBS with 10% serum (goat or donkey; Sigma) for 30 minutes at RT. Incubation with primary antibodies was performed at 4C ON, followed by appropriate secondary antibodies for 60 minutes at RT. Between all steps tissue sections were washed twice with PBS containing 2% BSA. Immuno-reactivity was detected using different peroxidasebased systems according to the manufacturer's instructions (Vector Laboratories, Peterborough, UK). For immunofluorescence, the secondary antibodies conjugated with Alexa488 and Alexa594 (Invitrogen-Life Technologies, Paisley, UK) were used.
Sections were counterstained with hematoxylin, dehydrated, and mounted with DePex mounting medium (BDH, Lutterworth, UK) or with fluorescence mounting medium containing DAPI.
Cell Lines
293HEK, HeLa and MCF7 were grown in DMEM-GlutaMAX TM ; HL60, Jurkat, K562, Molt4, Raji, U937 and U266 were grown in RPMI1640-GlutaMAX TM ;
Saos2 in IMDM and all S17 stromal lines were grown in MEM-nucleosidesGlutaMAX TM . All media was supplemented with 10% FBS and 1x Pen-Strep and all reagents were from Gibco ® -Life Technologies. The parental S17 stromal cell line and S17-Dll1 and S17-Jag1 were kindly provided by Dr. Anne-Marie Buckle and S17-Dll4 by Dr. Evelyne Lauret. Briefly, S17-Dll1, S17-Dll4 and S17-Jag1 were retrovirally transduced to overexpress the full length of human Delta1, Delta4 and Jagged1 respectively and vectors carry puromycin resistant gene for selection. All other cells lines were from CRUK Cell Services.
Cell culture and Transient Transfection
Cultures were initiated by plating 10,000 -/-/+ or 5,000 of each of the different +/-sub-populations in one well of a 24-well plate pre-coated with the different S17 stromal cells (seeded 2-3 days before at 20,000 cells/cm 2 ) in 500 l of MEM/5%
FBS. The following cytokines were added once for the 5-day culture: SCF (100 ng/ml), Flt3-L (100 ng/ml) and TPO (50 ng/ml). To block Notch signalling, GSI IX (DAPT; Sigma) was added on day 2 and 4 at 10 M. To study TGF signalling, TGF1 was added alone on day 2 and 4 at 2.5 ng/ml or in combination with the ALK inhibitor SB431542 (Sigma) at 10 M or with the TGF1 blocking antibody (AF101NA, R&D Systems, Abingdon, UK) at 400 ng/ml.
For the TCF/LEF reporter assay, the different FACS purified CB populations were co-transfected with 0.9 g of 4x TOP-dGFP or FOP-dGFP plasmid with 0. Institute of Oncology), and human recombinant cytokines were sourced from Peprotech (London, UK).
Colony Assays
Standard methylcellulose colony assay media, MethoCult ® GF M3434
(StemCell Technologies), was used according to the manufacturer's instructions.
Colonies were scored at day 14. Colonies were harvested by washing with PBS and collected for the replating assay for an additional 14 days.
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Sorting Purity
To ensure high purity during cell sorting, sorts were performed at low speed (usually under 2000 events/second). Purity checks were performed to ensure sort quality. The purity of the -/-, -/-/+, +/-and the four +/-sub-fractions were >99%. On some occasions, re-sorting was performed when -/-or -/-/+ fractions were contaminated with >1% of the +/-fraction. Further to this, qRT-PCR for CD34 expression and CFC assay were routinely performed to validate the in vivo and in vitro experiments with -/-or -/-/+ fractions.
Analysis of Mouse BM
Animals were sacrificed at different time points indicated and the cells from the BM were harvested. BM aspiration was also performed using a similar method described above for the IB injection. Red blood cells were lysed and an aliquot of BM cells were immuno-phenotyped to determine the level and nature of human engraftment by FCM. Dead cells and debris were excluded using DAPI staining and >200,000 DAPI -events were collected. SybrGreen master mix reagent (Applied BioSystems, Carlsbad, CA, USA) was used and the amplification was done using the ABI Prism 7700 sequence detection system (Applied BioSystems). To avoid possible amplification of contaminating DNA and unprocessed mRNA, where possible, primers were designed to anneal the end parts of two exons. The specificity of the PCR products was verified by running a 2% agarose gel, in addition to using the dissociation curve software from the qRT-PCR system.
Primers used are listed in Table S2 .
Statistical analysis
Paired or un-paired t-tests were used accordingly for analyses. (A) Immunohistochemistry staining of Delta-1 (Dll1) on placenta tissue and umbilical cords. Human neoplastic small intestine tissue was served as positive control for Dll1 staining. Isotype-matched antibody staining was used as negative control staining (Ctrl.) on the respective serial section. Scale bars: 100m. (B) Up-regulation of CD34 expression and cell cycle progression in -/-/+ cells after coculture for 5 days on S17 or S17-Dll1 cells (n=2). (C) Primary (top graph) and secondary (bottom graph) CFU colonies derived from -/-/+ cells after being cultured for 5 days on S17 or S17-Dll1 cells (n=3, each in triplicate). (D) Pertentage of apoptosis in -/-/+ cells that have been cultured on S17 cells expressing the indicated ligand. (E) Expression of pro-apoptotic genes, BAD, BAK1 and BAX in -/-/+ cells that have been cultured on S17 cells expressing the indicated ligand. Cells cultured on S17 were used as reference (n=3). (F) Cell cycle analysis and CD34 expression in -/-/+ cells after co-culture for 5 days on S17 cells expressing the indicated ligand treated with vehicle (DMSO) or DAPT (n=2) (G) A representative electrophoresis gel picture showing the expression of DELTEX1 in non-cultured -/-/+ HSCs (NC) and after co-culture on the different ligand-expressing S17 stromal cell lines for 5 days. Non-template (NT) and GAPDH were used as negative and positive controls respectively (n=4). (H) qRT-PCR for the expression of differentiation genes in different +/-sub-populations after 5 days of cultures on S17 or S17-Dll4 stromal cells. The 90
+ population cultured on S17 was used as reference population (n=3-5). (I) Expression of cell cycle regulator genes in different +/-subpopulations after 5 days of cultures on S17 or S17-Jag1 stromal cells (n=3) 
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5'-CTTTCAACCACTAGCACTAGCC-3' 5'-TGCCCTGAGTCAATTTCACTTC-3' GAPDH 5'-GGGAAGGTGAAGGTCGGAGT-3' 5'-GGGTCATTGATGGCAACAATA-3' HOXA5 5'-GCGCAAGCTGCACATAAGTC-3' 5'-CGTCCGGGCCCTTTTG-3' HOXA9 5'-GCGCCTTCTCTGAAAACAAT -3' 5'-AGTGGAGCGCGCATGAA -3' MEIS1 5'-GGGCTCCTCTGTCAATGACG-3' 5'-GGCGAACACGGCTATATCTTC-3'
